Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported an open-market purchase of 1,191 shares of the company’s Common Stock on May 15, 2026. After this transaction, she directly owns a total of 620,622 Common Stock shares.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported routine equity compensation activity. On May 14, she acquired 13,977 shares of common stock through the vesting of restricted stock units, while 7,326 shares were withheld at $3.94 per share to cover tax obligations.
KORU Medical Systems Chief Operating Officer Christopher Pazdan reported routine equity compensation activity. On the vesting of restricted stock units, he acquired 5,327 shares of common stock and 1,470 shares were withheld to satisfy tax obligations at a value of $3.94 per share. Following these transactions, he holds just over 310,000 shares directly.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan bought 5,000 shares of Common Stock in an open-market purchase at $3.88 per share. Following this transaction, he directly owns 305,131 shares.
KORU Medical Systems Chief Financial Officer Thomas Edward Adams reported routine equity compensation activity involving restricted stock units. On May 14, 2026, common stock was issued upon vesting of RSUs, each unit representing a contingent right to receive one share of common stock upon vesting.
In connection with this vesting, 2,900 shares of common stock were disposed of at $3.94 per share to satisfy tax obligations, while 8,193 shares were acquired through a derivative exercise/conversion. Following these transactions, Adams directly holds 313,440 shares of KORU Medical common stock. These are not open-market buy or sell transactions but compensation-related events.
KORU Medical Systems, Inc. Chief Financial Officer Thomas Edward Adams bought additional company stock in the open market. He purchased a total of 5,500 shares of common stock in two open-market transactions, paying $3.90 and $3.86 per share.
KORU Medical Systems, Inc. reported first-quarter 2026 net revenues of $11.8 million, up 22.1% from $9.6 million a year earlier, driven by growth across domestic, international, and pharma services businesses. Domestic core revenue rose 11.7%, international core grew 35.2%, and pharma services and clinical trials increased 166.0%.
Gross profit increased to $7.2 million, although gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Operating expenses rose 11.0% to $8.1 million, mainly from higher legal and compensation costs. Net loss narrowed to $0.8 million, or $0.02 per share, compared with a $1.2 million loss, or $0.03 per share, in the prior-year quarter.
The company ended the quarter with $8.8 million in cash and cash equivalents and $4.5 million of inventory, and generated essentially break-even operating cash flow. KORU amended its $10 million credit facility, extending maturities, lowering the interest rate floor to 5.50%, and lengthening the interest-only period on the term loan. The company expects existing cash, operations, and available credit to fund its needs for at least the next twelve months.
KORU Medical Systems reported strong first quarter 2026 growth while remaining modestly loss-making. Net revenues rose 22.1% to $11.8 million, driven by 11.7% domestic core growth to $7.7 million, 35.2% international core growth to $3.3 million, and 166.0% growth in pharma services and clinical trials to $0.7 million.
Gross profit increased to $7.2 million, though gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Net loss improved to $0.8 million, or $0.02 per diluted share, from $1.2 million, or $0.03 per diluted share, with adjusted EBITDA near breakeven at negative $0.01 million.
Cash and cash equivalents were $8.8 million as of March 31, 2026, with minimal cash usage of about $0.1 million in the quarter. The company reiterated full-year 2026 guidance for net revenues of $47.5–$50.0 million, gross margin of 61–63%, and positive adjusted EBITDA and positive cash flow.
BlackRock, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 2,292,477 shares of Koru Medical Systems Inc. The filing states BlackRock has 2,256,191 shares of sole voting power, represents 4.9% of the class, and is signed by a Managing Director.